Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Abstract 2881: Deubiquitinase Usp9x controls tumorigenicity through regulation of the Ets-1 transcription factor in melanoma

Harish Potu, Luke F. Peterson Peterson, Malathi Kandarpa Kandarpa, Anupama Pal Pal, Hanshi Sun Sun, Paul W. Harms Harms, Peter C. Hollenhorst Hollenhorst, Ugur Eskiocak Eskiocak, Moshe Talpaz Talpaz, Nicholas J. Donato Donato

Cancer Res (2016) 76 (14_Supplement): 2881.

https://doi.org/10.1158/1538-7445.AM2016-2881

Published: 15 July 2016

View articletitled, Abstract 2881: Deubiquitinase Usp9x controls tumorigenicity through regulation of the Ets-1 transcription factor in melanoma

Journal Articles

Abstract 3621: Deubiquitination of AXIN1 by USP9X promotes apoptosis in melanoma in response to BRAF or MEK inhibition

Harish Potu, Luke F. Peterson, Malathi Kandarpa, Eric Fearon, Moshe Talpaz, Nicholas J. Donato

Cancer Res (2015) 75 (15_Supplement): 3621.

https://doi.org/10.1158/1538-7445.AM2015-3621

Published: 01 August 2015

View articletitled, Abstract 3621: Deubiquitination of AXIN1 by USP9X promotes apoptosis in melanoma in response to BRAF or MEK inhibition

Journal Articles

Abstract 4435: Deubiquitinases Usp9x and Usp5 control tumorigenicity and apoptotic responsiveness in malignant melanoma

Harish Potu, Anupama Pal, Hanshi Sun, Luke Peterson, Moshe Talpaz, Monique Verhaegen, Juxiang Cao, Ugur Eskiocak, Sean Morrison, Nicholas J. Donato

Cancer Res (2014) 74 (19_Supplement): 4435.

https://doi.org/10.1158/1538-7445.AM2014-4435

Published: 01 October 2014

View articletitled, Abstract 4435: Deubiquitinases Usp9x and Usp5 control tumorigenicity and apoptotic responsiveness in malignant melanoma

Journal Articles

Abstract 4434: Role of Deubiquitinase Usp9x in pancreatic cancers: Tumor promoter or tumor suppressor

Anupama Pal, Marina Pasca di Magliano, Moshe Talpaz, Michelle Dziubinski, Diane Simeone, Nicholas J. Donato

Cancer Res (2014) 74 (19_Supplement): 4434.

https://doi.org/10.1158/1538-7445.AM2014-4434

Published: 01 October 2014

View articletitled, Abstract 4434: Role of Deubiquitinase Usp9x in pancreatic cancers: Tumor promoter or tumor suppressor

Journal Articles

Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of Cancer

Anupama Pal, Matthew A. Young, Nicholas J. Donato

Cancer Res (2014) 74 (18): 4955–4966.

https://doi.org/10.1158/0008-5472.CAN-14-1211

Published: 14 September 2014

View articletitled, Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of Cancer

Journal Articles

Abstract 2323: Mutant B-Raf-mediated activation of deubiquitinases in melanoma defines Usp5 as a potential therapeutic target.

Harish Potu, Luke F. Peterson, Monique Verhaegen, Moshe Talpaz, Nicholas J. Donato

Cancer Res (2013) 73 (8_Supplement): 2323.

https://doi.org/10.1158/1538-7445.AM2013-2323

Published: 15 April 2013

View articletitled, Abstract 2323: Mutant B-Raf-mediated activation of deubiquitinases in melanoma defines Usp5 as a potential therapeutic target.

Journal Articles

Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis

Vaibhav Kapuria, Luke F. Peterson, Dexing Fang, William G. Bornmann, Moshe Talpaz, Nicholas J. Donato

Cancer Res (2010) 70 (22): 9265–9276.

https://doi.org/10.1158/0008-5472.CAN-10-1530

Published: 14 November 2010

View articletitled, Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis

Includes: Supplementary data

Journal Articles

Sub-cellular compartmentalization of Jak2 as a unique mechanism for the inhibition of Jak2-Stat3 signaling

Vaibhav Kapuria, Geoffrey Bartholomeusz, Ling Y Kong, William G Bornmann, Nicholas J Donato

Cancer Res (2007) 67 (9_Supplement): 2390.

Published: 01 May 2007

View articletitled, Sub-cellular compartmentalization of Jak2 as a unique mechanism for the inhibition of Jak2-Stat3 signaling

Journal Articles

Degrasyn Activates Proteasomal-Dependent Degradation of c-Myc

Geoffrey Bartholomeusz, Moshe Talpaz, William Bornmann, Ling-Yuan Kong, Nicholas J. Donato

Cancer Res (2007) 67 (8): 3912–3918.

https://doi.org/10.1158/0008-5472.CAN-06-4464

Published: 17 April 2007

View articletitled, Degrasyn Activates Proteasomal-Dependent Degradation of c-Myc

Journal Articles

Small molecule, peptidomimetic prodrugs as inhibitors of signal transducer and activator of transcription 3

Pijus K. Mandal, Warren Liao, Zhiyong Ren, Xioamin Chen, Nicholas J. Donato, John S. McMurray

Cancer Res (2006) 66 (8_Supplement): 1112.

Published: 15 April 2006

View articletitled, Small molecule, peptidomimetic prodrugs as inhibitors of signal transducer and activator of transcription 3

Journal Articles

Silencing Lyn kinase overcomes resistance to imatinib in Bcr-Abl-dependent CML cells

Ji Yuan Wu, Moshe Talpaz, Nicholas J. Donato

Cancer Res (2006) 66 (8_Supplement): 554.

Published: 15 April 2006

View articletitled, Silencing Lyn kinase overcomes resistance to imatinib in Bcr-Abl-dependent CML cells

Journal Articles

Inhibition of c-Src expression and kinase activity inhibit progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Justin M. Summy, Jose G. Trevino, Donald P. Lesslie, Nila U. Parikh, David S. Hong, Francis Y. Lee, Nicholas J. Donato, Cheryl H. Baker, Gary E. Gallick

Cancer Res (2006) 66 (8_Supplement): 1198.

Published: 15 April 2006

View articletitled, Inhibition of c-Src expression and kinase activity inhibit progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Journal Articles

Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma

Donald P. Lesslie, III, Nila U. Parikh, Ami Shah, Justin M. Summy, Jose G. Trevino, David Hong, Nicholas J. Donato, Francis Y. Lee, Gary E. Gallick

Cancer Res (2006) 66 (8_Supplement): 1114.

Published: 15 April 2006

View articletitled, Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma

Journal Articles

A role for Src-family kinases in imatinib resistant chronic myelogenous leukemia

Nicholas J. Donato, Ji Y. Wu, Ling Y. Kong, Francis Lee, Moshe Talpaz

Cancer Res (2005) 65 (9_Supplement): 353.

Published: 01 May 2005

View articletitled, A role for Src-family kinases in imatinib resistant chronic myelogenous leukemia

Journal Articles

Discovery of WP1066, a novel Stat3/c-myc inhibitor with potent antitumor activity against human melanoma in vitro and in vivo

Ling Y. Kong, Waldemar Priebe, Moshe Talpaz, Nicholas J. Donato

Cancer Res (2005) 65 (9_Supplement): 1387.

Published: 01 May 2005

View articletitled, Discovery of WP1066, a novel Stat3/c-myc inhibitor with potent antitumor activity against human melanoma in vitro and in vivo

Journal Articles

BMS-354825 multiple oncogenic tyrosine kinase inhibitor induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cells

Faye M. Johnson, Babita Saigal, Moshe Talpaz, Nicholas J. Donato

Cancer Res (2005) 65 (9_Supplement): 159.

Published: 01 May 2005

View articletitled, BMS-354825 multiple oncogenic tyrosine kinase inhibitor induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cells

Journal Articles

Imatinib mesylate suppresses T-cell activation through inhibition of Lck/Zap-70 signaling: Evidence for a role in herpes zoster reactivation in CML patients

Nicholas J. Donato, Moshe Talpaz, Ji Y. Wu, Hui Gao, Bang-Ning Lee, Hagop Kantarjian, Daniel Lohse, Raymond Budde, James M. Reuben

Cancer Res (2004) 64 (7_Supplement): 284.

Published: 01 April 2004

View articletitled, Imatinib mesylate suppresses T-cell activation through inhibition of Lck/Zap-70 signaling: Evidence for a role in herpes zoster reactivation in CML patients

Journal Articles

Control of BCR-ABL activation by SHP-1: Role in chronic myelogenous leukemia disease progression and imatinib resistance.

Nicholas J. Donato, Ji Y. Wu, Koyu Hoshino, Hagop Kantarjian, Moshe Talpaz, Guillermo Garcia-Manero

Cancer Res (2004) 64 (7_Supplement): 560.

Published: 01 April 2004

View articletitled, Control of BCR-ABL activation by SHP-1: Role in chronic myelogenous leukemia disease progression and imatinib resistance.

Journal Articles

The SRC/ABL kinase inhibitor BMS-354825 induces apoptosis and overcomes imatinib resistance in chronic myelogenous leukemia cell lines and patient specimens

Ji Y. Wu, Nicholas J. Donato, David S. Hong, Francis Y. Lee, Moshe Talpaz

Cancer Res (2004) 64 (7_Supplement): 888.

Published: 01 April 2004

View articletitled, The SRC/ABL kinase inhibitor BMS-354825 induces apoptosis and overcomes imatinib resistance in chronic myelogenous leukemia cell lines and patient specimens

Journal Articles

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Nicholas J. Donato, Ji Y. Wu, Jonathan Stapley, Hui Lin, Ralph Arlinghaus, Bharat Aggarwal, Shishir Shishodin, Maher Albitar, Kimberly Hayes, Hagop Kantarjian, Moshe Talpaz

Cancer Res (2004) 64 (2): 672–677.

https://doi.org/10.1158/0008-5472.CAN-03-1484

Published: 26 January 2004

View articletitled, Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 2881: Deubiquitinase Usp9x controls tumorigenicity through regulation of the Ets-1 transcription factor in melanoma

Abstract 3621: Deubiquitination of AXIN1 by USP9X promotes apoptosis in melanoma in response to BRAF or MEK inhibition

Abstract 4435: Deubiquitinases Usp9x and Usp5 control tumorigenicity and apoptotic responsiveness in malignant melanoma

Abstract 4434: Role of Deubiquitinase Usp9x in pancreatic cancers: Tumor promoter or tumor suppressor

Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of Cancer

Abstract 2323: Mutant B-Raf-mediated activation of deubiquitinases in melanoma defines Usp5 as a potential therapeutic target.

Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis

Sub-cellular compartmentalization of Jak2 as a unique mechanism for the inhibition of Jak2-Stat3 signaling

Degrasyn Activates Proteasomal-Dependent Degradation of c-Myc

Small molecule, peptidomimetic prodrugs as inhibitors of signal transducer and activator of transcription 3

Silencing Lyn kinase overcomes resistance to imatinib in Bcr-Abl-dependent CML cells

Inhibition of c-Src expression and kinase activity inhibit progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma

A role for Src-family kinases in imatinib resistant chronic myelogenous leukemia

Discovery of WP1066, a novel Stat3/c-myc inhibitor with potent antitumor activity against human melanoma in vitro and in vivo

BMS-354825 multiple oncogenic tyrosine kinase inhibitor induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cells

Imatinib mesylate suppresses T-cell activation through inhibition of Lck/Zap-70 signaling: Evidence for a role in herpes zoster reactivation in CML patients

Control of BCR-ABL activation by SHP-1: Role in chronic myelogenous leukemia disease progression and imatinib resistance.

The SRC/ABL kinase inhibitor BMS-354825 induces apoptosis and overcomes imatinib resistance in chronic myelogenous leukemia cell lines and patient specimens

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only